Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Niban CRISPR/Cas9 KO Plasmid (h): sc-405758
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Niban CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Niban genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Niban Antibody (F-10): sc-374636
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Niban CRISPR/Cas9 KO Plasmid (h) | sc-405758 | 20 µg | $397.00 |
Overview
FAM129A encodes Niban, a stress-responsive cytoplasmic protein implicated in regulation of cell survival and adaptation to adverse conditions such as oxidative and endoplasmic reticulum stress. Niban has been linked to modulation of apoptosis and autophagy-associated signaling and is frequently studied in the context of PI3K/AKT and MAPK pathway outputs that shape proliferation and stress tolerance. Altered FAM129A expression has been reported across multiple cancer types and is used as a molecular readout of tumor cell fitness and stress adaptation. These features make Niban a useful target for dissecting signaling networks that couple cellular stress responses to growth control.
Niban CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FAM129A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FAM129A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FAM129A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Niban protein expression.
This CRISPR knockout system enables efficient generation of FAM129A-deficient cell models for investigation of Niban signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FAM129A exon(s) critical for Niban function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FAM129A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Niban CRISPR/Cas9 KO Plasmid (h) and Niban CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FAM129A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Niban HDR Plasmid (h) and Niban HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FAM129A homology arms to support homology-directed repair at defined FAM129A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.